Oxford COVID-19 vaccine shows promising immune response among elderly people

Gov. De Santis said Thursday that the state is prepared to distribute the vaccine as quickly and efficiently as possible

Gov. De Santis said Thursday that the state is prepared to distribute the vaccine as quickly and efficiently as possible

Sinovac Biotech's CoronaVac vaccine can produce antibody responses in two doses given 14 days apart over 28 days, British medical journal Lancet revealed in a new study.

Zhu added that further research is needed to verify the duration of the immune response induced by the vaccination.

The encouraging findings are based on 560 healthy adults and comes a day after Pfizer announced its coronavirus vaccine was 95 percent effective among adults over 65 in its final efficacy results.

The ongoing pandemic has seen numerous countries race for an effective vaccine against COVID-19, with Sinovac running phase 3 trials in Brazil, Indonesia and Turkey, Reuters reported.

The experimental vaccines are undergoing Phase 3 clinical trials overseas that have recruited almost 60,000 people, and blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, the article said citing Liu, without breaking down the numbers for each vaccine.

The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2.

These trial results from the University of Oxford, peer-reviewed in the Lancet, suggest that may not be a problem.

"The next step will be to see if this translates into protection from the disease itself". "We will need all of them to protect people around the globe", he said.

Older adults were also less likely to experience side-effects, which were usually mild.

Between the phase 1 and phase 2 trials, the researchers changed the manufacturing process of the vaccine to increase production capacity.

The Oxford vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees that has been modified so it can not grow in humans.

Two groups of 72 volunteers were randomly given low, high and placebo doses of the vaccine, with 96 receiving the former two doses of CoronaVac and 47 the latter, respectively. "It's an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines".

News of the vaccine comes amid a debate in the United Kingdom about whether people will be able to see their families over the Christmas period.

Prof Andrew Hayward - director of the UCL Institute of Epidemiology and Health Care and a member of the government's Scientific Advisory Group for Emergencies - told the BBC that family gatherings at Christmas would pose "substantial risks". "We just don't know", she adds.

Cyberpunk 2077 new gameplay trailer headlines latest edition of Night City Wire